NPPA has revised ceiling price of 24 formulations and retail price of 31 formulations which includes from anticancer, antidiabetic, antiviral, antibacterial, antifungal etc portfolios.
NPPA notified in their notice that "all the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price."
This price cut will effect companies like Ajanta Pharma, Glenmark Pharmaceuticals, Alkem Lab, Aristo Pharmaceuticals, Panacea Biotec, Cadila Healthcare, Medley Pharma, Cadila Pharma etc.
They also notified that the manufacturers, not complying with the ceiling price, shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
